


What is claimed is:

1. A compound according to Formula (1):



- 5 wherein:

X is selected from the group consisting of  $\text{CH}_2$ ,  $\text{NR}_2$ ,  $\text{O}$ ,  $\text{NR}_2\text{CO}$ ,  $\text{CONR}_2$  and a bond;

Y represents  $\text{O}$ ,  $\text{CH}_2$  or a bond:

Z represents  $\text{H}$  or  $\text{F}$ ;

- 10 R is selected from the group consisting of:

$\text{C}_{2-6}$  alkyl optionally substituted by alkoxy, halogen, or  $\text{C}_{1-3}$  alkylsulfanyl;  $\text{C}_{2-6}$  alkenyl optionally substituted by alkoxy, halogen, or  $\text{C}_{1-3}$  alkylsulfanyl;  $\text{C}_{2-6}$  alkynyl optionally substituted by alkoxy, halogen, or  $\text{C}_{1-3}$  alkylsulfanyl;  $(\text{CH}_2)_n\text{—C}_{3-6}$  carbocycle optionally substituted by alkoxy, halogen, or  $\text{C}_{1-3}$  alkylsulfanyl;  $(\text{CH}_2)_n\text{—R}_3$  {where  $\text{R}_3$  is phenyl, furan, benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4-benzodioxane or benzo[1,3]dioxole;  $\text{R}_3$  is optionally substituted by one or more  $\text{Cl}$ ,  $\text{Br}$ ,  $\text{I}$ ,  $\text{C}_{1-3}$  alkyl optionally substituted by one to three  $\text{F}$ , or  $\text{C}_{1-2}$  alkoxy, optionally substituted by one to three  $\text{F}$ };

- 20  $\text{R}_1$  is selected from the group consisting of:

hydrogen,  $\text{C}_{1-3}$  substituted alkyl,  $\text{C}_{2-3}$  substituted alkenyl,  $\text{C}_{2-3}$  substituted alkynyl,  $(\text{CH}_2)_n\text{—C}_{3-6}$  substituted carbocycle, aryl, heteroaryl, heterocyclic, and aminocarbonyl provided that  $\text{X}$  is  $(\text{CH}_2)_n$  when  $\text{R}_1$  represents aminocarbonyl;

$\text{R}_2$  represents:


- 25 hydrogen, or  $\text{C}_{1-3}$  substituted alkyl;

$\text{X}$  represents  $(\text{CH}_2)_n$ ,  $\text{NR}_2$ ,  $\text{O}$ ,  $\text{NR}_2\text{CO}$ ,  $\text{CONR}_2$  or a bond;

$\text{Y}$  represents  $\text{O}$ ,  $\text{CH}_2$  or a covalent bond;

Z represents hydrogen or fluorine; preferably fluoroine; and n represents an interger between 0 and 2 or a salt, solvate, or physiologically functional derivative thereof.

2. A compound as claimed in claim 1, with the following absolute configuration:



5

wherein:

X is selected from the group consisting of  $\text{CH}_2$ ,  $\text{NR}_2$ ,  $\text{O}$ ,  $\text{NR}_2\text{CO}$ ,  $\text{CONR}_2$  and a bond;

Y represents  $\text{O}$ ,  $\text{CH}_2$  or a bond:

10 Z represents H or F;

3. A compound as claimed in claim 1, wherein  $\text{X} = \text{CH}_2$  or a bond; or a salt, solvate, or physiologically functional derivative thereof.

15 4. A compound as claimed in claim 1, wherein  $\text{X} = \text{NR}_2$ ; or a salt, solvate, or physiologically functional derivative thereof.

5. A compound according to claim 3 selected from the group consisting of:

N-[(R)-2-(5-Benzo[1,3]dioxol-5-yl-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxyformamide;

20 N-[(R)-2-(5-Benzyl-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxyformamide;

N-Hydroxy-N-{(R)-2-[5-(7-methoxy-benzofuran-2-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

N-Hydroxy-N-{(R)-2-[5-(1,2,3,4-tetrahydroquinolin-6-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

25 N-Hydroxy-N-{(R)-2-[5-(1,2,3,4-tetrahydro-quinolin-8-yl)-[1,3,4]oxadiazol-2-yl]-heptyl}-formamide;

N-Hydroxy-N-[(R)-2-(5-pyridin-3-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;

N-{(R)-2-[5-(3,4-Dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy-

- formamide;  
N-[(R)-2-[5-(3,4-Dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-N-hydroxy-  
formamide;  
N-[(R)-2-[5-(3,4-Dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-N-hydroxy-  
5 formamide;  
N-Hydroxy-N-[(R)-2-[5-(2-morpholin-4-yl-ethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-  
formamide;  
N-Hydroxy-N-[(R)-2-[5-(2-morpholin-4-yl-ethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-  
formamide;  
10 N-[(R)-2-[5-(2,3-Dichloro-phenoxy-methyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-N-  
hydroxy formamide;  
N-Hydroxy-N-[(R)-2-[5-(4-methoxy-phenoxy-methyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-  
formamide;  
N-[(R)-2-[5-[4-(4-Acetyl-piperazin-1-yl)-phenoxy-methyl]-[1,3,4]oxadiazol-2-yl]-  
15 heptyl]-N-hydroxy-formamide;  
N-Hydroxy-N-[(R)-2-[5-(1-methyl-1H-pyrrol-2-ylmethyl)-[1,3,4]oxadiazol-2-yl]-  
heptyl]-formamide;  
N-Hydroxy-N-[(R)-2-(5-pyridin-2-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-  
formamide;  
20 N-Hydroxy-N-[(R)-2-(5-pyridin-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-  
formamide;  
N-Hydroxy-N-[(R)-2-[5-(2,6-dichloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-  
formamide;  
N-Hydroxy-N-[(R)-2-[5-(1H-indol-3-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-  
25 formamide;  
N-[(R)-2-[(S)-5-(2,3-Dihydro-benzo[1,4]dioxin-2-yl)-[1,3,4]oxadiazol-2-yl]-  
heptyl]-N-hydroxy-formamide;  
N-[(R)-2-(5-Benzofuran-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxy-  
formamide;  
30 N-Hydroxy-N-[(R)-2-(5-pyrimidin-2-yl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;  
N-[(R)-2-[5-(2,3-Dihydro-benzo[d]isoxazol-3-ylmethyl)-[1,3,4]oxadiazol-2-yl]-

- heptyl}-N-hydroxy-formamide;  
N-Hydroxy-N-[(R)-2-(5-phenoxy-methyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;  
N-Hydroxy-N-[(R)-2-[(S)-5-(1,2,3,4-tetrahydro-isoquinolin-3-yl)-[1,3,4]oxadiazol-2-yl]-heptyl]-formamide;
- 5 N-Hydroxy-N-[(R)-2-[5-(4-imidazol-1-yl-phenoxy-methyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-formamide;  
N-Hydroxy-N-[(R)-2-[5-(quinolin-6-yloxy-methyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-formamide;  
5-{(R)-1-[(Formyl-hydroxy-amino)-methyl]-hexyl}-[1,3,4]oxadiazole-2-carboxylic  
10 acid phenylamide;  
N-Hydroxy-N-[(R)-2-(5-phenylaminomethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;  
N-[(R)-2-[5-(2-Chloro-benzyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-N-Hydroxy-formamide;
- 15 N-[(R)-2-(5-Benzyl-[1,3,4]oxadiazol-2-yl)-3-cyclohexyl-propyl]-N-hydroxyformamide.  
N-[(R)-2-[5-[2-(1H-Benzoimidazol-2-yl)-ethyl]-[1,3,4]oxadiazol-2-yl]-heptyl]-N-Hydroxy-formamide;  
N-Hydroxy-N-[(R)-2-[5-(4-pyrimidin-2-yl-piperazin-1-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-formamide;
- 20 N-Hydroxy-N-[(R)-2-[5-(3-methyl-isoxazol-5-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-formamide;  
N-Hydroxy-N-[(R)-2-[5-(5-methyl-2-phenyl-oxazol-4-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-formamide;  
N-Hydroxy-N-(2-{5-[4-trifluoromethyl-pyrimidin-2-ylamino)-methyl]-[1,3,4]oxadiazol-2-yl}-heptyl)-formamide;
- 25 [1,3,4]oxadiazol-2-yl}-heptyl)-formamide;  
N-[(R)-2-[5-(1H-Benzoimidazol-2-ylmethyl)-[1,3,4]oxadiazol-2-yl]-heptyl]-N-hydroxy-formamide;  
N-Hydroxy-N-[(R)-2-(5-morpholin-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;
- 30 N-Hydroxy-N-[(R)-2-[5-(3-trifluoromethyl-phenylamino)-methyl]-[1,3,4]oxadiazol-2-yl]-heptyl)-formamide;

N-[(R)-2-(5-Benzyl-[1,3,4]oxadiazol-2-yl)-3-cyclopentyl-propyl]-N-hydroxyformamide;  
 N-Hydroxy-N-[(R)-2-(5-methyl-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide; and  
 N-Hydroxy-N-((R)-2-{5-[2-(1H-indol-3-yl)-ethyl]-[1,3,4]oxadiazol-2-yl}-heptyl)-  
 formamide.

5

6. A compound according to claim 5 selected from the group consisting of:

N-Hydroxy--[(R)-2-(5-phenylamino-[1,3,4]oxadiazol-2-yl)-heptyl]-formamide;

N-(5-{(R)-1-[(Formyl-hydroxy-amino)-methyl]-hexyl}-[1,3,4]oxadiazol-2-yl)-

10 benzamide;

N-{(R)-2-[5-(Chloro-trifluoromethyl-phenylamino)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-  
 hydroxy-formamide;

N-Hydroxy-N-{(R)-2-[5-(methyl-phenyl-amino)-[1,3,4]oxadiazol-2-yl]-heptyl}-  
 formamide;

15 Benzo[1,3]dioxole-5-carboxylic acid (5-{(R)-1-[(formyl-hydroxy-amino)-methyl]-  
 hexyl}-[1,3,4]oxadiazol-1,2-yl)-amide;

N-{(R)-2-[5-(3,5-Dichloro-phenylamino)-[1,3,4]oxadiazol-2-yl]-heptyl}-N-hydroxy  
 formamide;

20 N-[(S)-2-Fluoro-2-(5-phenylamino-[1,3,4]oxadiazol-2-yl)-heptyl]-N-hydroxy  
 formamide; and

N-{(R)-2-[5-(2,3-Dihydro-benzo[1,4]dioxin-6-ylamino)-[1,3,4]oxadiazol-2-yl]-heptyl}-  
 N-hydroxy-formamide.

25 7. A method of treating a bacterial infection by administering to a subject in need  
 of treatment a compound according to claim 1.